Papsidero L D, Croghan G A, O'Connell M J, Valenzuela L A, Nemoto T, Chu T M
Cancer Res. 1983 Apr;43(4):1741-7.
Cloned hybridoma cell lines were obtained from fusions of murine myeloma cells with lymphocytes of mice immunized against human breast cancer cells. Hybridomas F36/22 and M7/105 produced antibodies whose binding to breast cancer cells could not be inhibited by prior absorptions with fibroblasts, lymphoblastoid cells, or erythrocytes. Results from cell surface binding assays using a panel of tumor cell lines indicated that antibodies F36/22 and M7/105 recognized determinants expressed maximally on breast cancer cells. Antibody F36/22 reacted with normal mammary epithelial membranes and milk fat globule membranes, whereas antibody M7/105 produced no detectable binding to these specimens. Antigens carrying these epitopes each showed reactivity with concanavalin A lectin. The determinant corresponding to antibody F36/22 was detectable in histological sections of a subset of breast tumors obtained at surgery.
克隆的杂交瘤细胞系是通过将小鼠骨髓瘤细胞与免疫过的小鼠淋巴细胞融合而获得的，这些小鼠淋巴细胞是针对人乳腺癌细胞进行免疫的。杂交瘤F36/22和M7/105产生的抗体，其与乳腺癌细胞的结合不能被预先用成纤维细胞、淋巴母细胞或红细胞吸收所抑制。使用一组肿瘤细胞系进行的细胞表面结合试验结果表明，抗体F36/22和M7/105识别在乳腺癌细胞上最大程度表达的决定簇。抗体F36/22与正常乳腺上皮膜和乳脂肪球膜发生反应，而抗体M7/105对这些标本未产生可检测到的结合。携带这些表位的抗原各自与伴刀豆球蛋白A凝集素显示出反应性。在手术获得的一部分乳腺肿瘤的组织切片中可检测到与抗体F36/22相对应的决定簇。
